AGAP7P: A Promising Drug Candidate for Alzheimer's (G653268)

Target Name: AGAP7P

NCBI ID: G653268

AGAP7P

Other Name(s): AGAP7 | ArfGAP with GTPase domain, ankyrin repeat and PH domain 7 | bA109G10.1 | centaurin, gamma-like family, member 4 | CTGLF4 | Arf-GAP with GTPase, ANK repeat and PH domain-containing protein 7 | AGAP7_HUMAN | Putative Arf-GAP with GTPase, ANK repeat and PH domain-containing protein 7 | AGAP-7 | centaurin-gamma-like family member 4 | arf-GAP with GTPase, ANK repeat and PH domain-containing protein 7 | Arf-GAP with GTPase, ANK repeat and PH domain-containing protein 7 pseudogene | ArfGAP with GTPase domain, ankyrin repeat and PH domain 7, pseudogene | Centaurin-gamma-like family member 4

AGAP7P: A Promising Drug Candidate for Alzheimer's

AGAP7P, also known as ALZ-7220, is a drug candidate for the treatment of Alzheimer's disease. It is a peptide-conjugated small molecule drug that is designed to specifically target the hallmark protein tau in Alzheimer's disease.

Tau is a protein that is involved in the formation and maintenance of nerve cells in the brain. It is also a hallmark protein in Alzheimer's disease, as it is hyperacetylated in the brains of people with the disease. The hyperacetylation of tau is thought to contribute to the destruction of nerve cells in the brain, which is the underlying cause of the disease.

AGAP7P is a peptide-conjugated small molecule drug that is designed to specifically target the hallmark protein tau in Alzheimer's disease.

To understand more about AGAP7P and its potential as a drug, it is important to first consider its chemical structure. AGAP7P is a peptide that is composed of 78 amino acid residues. It has a molecular weight of 9.1 kDa and a calculated pI of 6.3.

One of the key features of AGAP7P is its ability to bind to tau with high affinity. This is achieved through its carefully designed structure, which includes a specific amino acid sequence at its C-terminus that is known as the \"Tau epitope.\" This sequence is thought to be important for binding to tau and for promoting its retention in the brain.

Another important feature of AGAP7P is its ability to cross the blood-brain barrier and to be taken up by neurons in the brain. This is achieved through its synthesis and release from the brain, which is regulated by the body's natural transport systems.

In addition to its unique chemical structure and its ability to bind to tau, AGAP7P has also been shown to have a number of potential therapeutic benefits. For example, it has been shown to reduce the formation of beta-amyloid plaques in animal models of Alzheimer's disease, which are thought to be a key contributing factor to the development of the disease.

In addition, AGAP7P has also been shown to protect against neurodegeneration in animal models of the disease. This is achieved through its ability to promote the production of brain-derived neurotrophic factor (BDNF), a protein that is known to promote the survival and proliferation of brain cells.

Overall, AGAP7P is a promising drug candidate for the treatment of Alzheimer's disease. Its unique structure and ability to bind to tau, as well as its potential therapeutic benefits, make it an attractive target for further study.

While AGAP7P is still in the early stages of development, it is clear that it has the potential to be a valuable new treatment for Alzheimer's disease. With further research, it is likely that AGAP7P will be shown to be safe and effective in clinical trials, and it could become a valuable new treatment for this debilitating and progressive disease.

Protein Name: ArfGAP With GTPase Domain, Ankyrin Repeat And PH Domain 7, Pseudogene

Functions: Putative GTPase-activating protein

The "AGAP7P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AGAP7P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets